Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies
Diseases · 23.02.2026 · 14 (2) · 83
DOI: 10.3390/diseases14020083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diseases, online erschienen am 23.02.2026. Verfasst von Silvia Afonso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, Department of Medical Sciences, University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, Fundação para a Ciência e a Tecnologia, European Regional Development Fund.
Abstract (Originalsprache)
Background/Objectives: Cannabinoids are increasingly recognised for their therapeutic potential beyond well-established indications such as chronic pain, multiple sclerosis, and specific epileptic syndromes. Recent advances have highlighted their possible role in less-common or orphan diseases, opening new avenues for pharmaceutical research and clinical application.
Methods
This review provides a critical synthesis of the most recent evidence (2020–2025), available in PubMed and Scopus, regarding the use of cannabinoids in conditions including refractory epilepsies beyond Dravet and Lennox–Gastaut syndromes, movement disorders such as dystonia and Tourette syndrome, rare dermatological diseases like epidermolysis bullosa, and emerging data in Crohn’s disease.
Results
Negative outcomes, such as those reported in Fragile X syndrome trials, are also discussed as instructive examples of methodological and pharmacological challenges. Particular attention is given to the optimisation of pharmaceutical formulations and advanced separation technologies, including oromucosal sprays, transdermal gels, and novel nanocarrier systems, which aim to overcome issues of bioavailability and variability in patient response. Finally, safety concerns, regulatory aspects, and the need for robust clinical trials are addressed.
Conclusions
Overall, cannabinoids represent a promising yet underexplored therapeutic option in rare and complex disorders, warranting further investigation supported by innovative pharmaceutical approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Health Sciences, Department of Medical Sciences, University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal.
- Centre for the Research and Technology of Agroenvironmental and Biological Sciences, CITAB, Inov4Agro, University of Trás-os-Montes and Alto Douro, UTAD, Quinta de Prados, 5000-801 Vila Real, Portugal.
- RISE-Health, Faculty of Health Sciences, Department of Medical Sciences, University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal.
- Laboratory of Pharmacotoxicology, UBIMedical, University of Beira Interior, EM506, 6200-000 Covilhã, Portugal.
- Beiras Academic Clinical Center (CACB)-Group of "Problemas Relacionados com Toxicofilias", UBIMedical, EM506, 6200-000 Covilhã, Portugal.
ORCID-Profile: Joana Gonçalves, Ana T Brinca, Luana M Rosendo, Tiago Rosado, Ana Paula Duarte, Eugenia Gallardo
Förderung
- Fundação para a Ciência e Tecnologia
- Fundação para a Ciência e a Tecnologia
- European Regional Development Fund
Zitieren
APA
Afonso, S., Gonçalves, J., Brinca, A. T., Rosendo, L. M., Rosado, T., Duarte, A. P., & Gallardo, E. (2026). Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies. Diseases, 14(2), 83. https://doi.org/10.3390/diseases14020083
Vancouver
Afonso S, Gonçalves J, Brinca AT, Rosendo LM, Rosado T, Duarte AP, et al. Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies. Diseases. 2026;14(2):83. doi:10.3390/diseases14020083
BibTeX
@article{Afonso2026,
author = {Afonso, Silvia and Gonçalves, Joana and Brinca, Ana T and Rosendo, Luana M and Rosado, Tiago and Duarte, Ana Paula and Gallardo, Eugenia},
title = {Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies},
journal = {Diseases},
year = {2026},
volume = {14},
number = {2},
pages = {83},
doi = {10.3390/diseases14020083}
}
EUVIMED